CN111315771B - 针对mfap4的抗体 - Google Patents

针对mfap4的抗体 Download PDF

Info

Publication number
CN111315771B
CN111315771B CN201880070581.2A CN201880070581A CN111315771B CN 111315771 B CN111315771 B CN 111315771B CN 201880070581 A CN201880070581 A CN 201880070581A CN 111315771 B CN111315771 B CN 111315771B
Authority
CN
China
Prior art keywords
ligand
seq
antibodies
ser
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880070581.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN111315771A (zh
Inventor
格里斯·莱克·索伦森
安德斯·施洛瑟
乌菲·霍姆斯科夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syddansk Universitet
Original Assignee
Syddansk Universitet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syddansk Universitet filed Critical Syddansk Universitet
Publication of CN111315771A publication Critical patent/CN111315771A/zh
Application granted granted Critical
Publication of CN111315771B publication Critical patent/CN111315771B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201880070581.2A 2017-11-01 2018-11-01 针对mfap4的抗体 Active CN111315771B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17199552 2017-11-01
EP17199552.5 2017-11-01
PCT/EP2018/079949 WO2019086580A1 (en) 2017-11-01 2018-11-01 Antibodies against mfap4

Publications (2)

Publication Number Publication Date
CN111315771A CN111315771A (zh) 2020-06-19
CN111315771B true CN111315771B (zh) 2023-10-27

Family

ID=60201899

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880070581.2A Active CN111315771B (zh) 2017-11-01 2018-11-01 针对mfap4的抗体

Country Status (7)

Country Link
US (1) US11993649B2 (enExample)
EP (1) EP3704147A1 (enExample)
JP (1) JP7382343B2 (enExample)
CN (1) CN111315771B (enExample)
AU (1) AU2018359635B2 (enExample)
CA (1) CA3118361A1 (enExample)
WO (1) WO2019086580A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3213181A1 (en) 2021-04-12 2022-10-20 Grith Lykke Sorensen Mfap4 and treatment of fibrosis
WO2025242098A1 (zh) * 2024-05-21 2025-11-27 康诺亚生物医药科技（成都）有限公司 针对ceacam5的抗体偶联药物及其用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014114298A1 (en) * 2013-01-23 2014-07-31 Syddansk Universitet Mfap4 binding antibodies blocking the interaction between mfap4 and integrin receptors
WO2016008498A1 (en) * 2014-07-17 2016-01-21 Syddansk Universitet Mfap4 binding antibody blocking the interaction between mfap4 and integrin receptors
CN106771201A (zh) * 2016-12-05 2017-05-31 江西惠肽生物科技有限公司 用于肝纤维化诊断试剂盒及其检测方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110059097A1 (en) * 2008-02-22 2011-03-10 University Health Network MFAP4 as a Marker For Regulatory Cells and Anti-Cancer Cells
JP5872805B2 (ja) 2011-07-07 2016-03-01 花王株式会社 Ｍｆａｐ−４産生促進剤

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014114298A1 (en) * 2013-01-23 2014-07-31 Syddansk Universitet Mfap4 binding antibodies blocking the interaction between mfap4 and integrin receptors
WO2016008498A1 (en) * 2014-07-17 2016-01-21 Syddansk Universitet Mfap4 binding antibody blocking the interaction between mfap4 and integrin receptors
CN106771201A (zh) * 2016-12-05 2017-05-31 江西惠肽生物科技有限公司 用于肝纤维化诊断试剂盒及其检测方法

Also Published As

Publication number Publication date
CA3118361A1 (en) 2019-05-09
US20230047179A1 (en) 2023-02-16
CN111315771A (zh) 2020-06-19
EP3704147A1 (en) 2020-09-09
AU2018359635A1 (en) 2020-05-07
JP7382343B2 (ja) 2023-11-16
AU2018359635B2 (en) 2024-11-14
WO2019086580A1 (en) 2019-05-09
AU2018359635A2 (en) 2020-05-21
US11993649B2 (en) 2024-05-28
JP2021513360A (ja) 2021-05-27

Similar Documents

Publication Publication Date Title
CA2850824C (en) Treatment of ocular disease
AU2017299581B2 (en) Humanized monoclonal antibodies that target ve-ptp (hptp-β)
JP5990511B2 (ja) 血管新生に基づく眼障害の処置のための抗ｃｄ１６０特異的抗体
US20240343791A1 (en) Bispecific fusion polypeptide and application thereof
JP2008512349A (ja) タンパク質の安定な液体処方物および凍結乾燥処方物
CN109496149B (zh) 抗体及其药物缀合物的制剂
CN116096896B (zh) 一种含抗体药物偶联物的药物组合物及其用途
TW202528344A (zh) 眼科疾病之個人化治療
WO2022059800A1 (en) Bispecific binding molecules against vegf and ang2
CN111315771B (zh) 针对mfap4的抗体
EP4628512A1 (en) Trispecific fusion protein and use thereof
US20230364185A1 (en) VEGFR Fusion Protein Pharmaceutical Composition
TW202246351A (zh) Htra1結合劑及其使用方法
JP6921943B2 (ja) 増加した眼球保持を伴う眼科用融合タンパク質
JP7560185B2 (ja) 補体経路阻害剤及び血管新生阻害剤を含む融合タンパク質並びにその使用
TW202228790A (zh) 用於長效經眼遞送之非共價蛋白質－玻尿酸結合物
US20240067711A1 (en) Anti-vegf hexameric antibody and composition comprising same
KR20220029343A (ko) 항-ｖｅｇｆ 육량체 항체, 및 이를 포함하는 조성물
JP2025534971A (ja) 安定かつ強力な抗血管新生ｓｃｆｖフラグメントおよびそのｖｅｇｆ拮抗薬としての使用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant